FY2026 · ended Jun 30, 2026 · Revenue $4.22M, +38.1% YoY · Filed Aug 19, 2026
Intelligent Bio Solutions Inc. (INBS) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $4.2 million and a net loss of $12.4 million. Free cash flow was -$12.1 million. As of Jun 30, 2026 it held $4.0 million in cash and investments and $1.8 million in total debt.
Revenue
$4.22M
+38.1% vs prior year
Net income
$-12.43M
-17.6% vs prior year
Operating cash flow
$-11.93M
-23.2% vs prior year
Free cash flow
$-12.05M
-21.6% vs prior year
EPS
$-8.44
+57.9% vs prior year
Dividend per share
None
Shares outstanding
3.03M
-66.3% vs prior year
Net cash
$2.17M
FY 2026
Operating margin
-299.1%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- INBS (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1725430
- Former names
- GBS Inc. (until Oct 18, 2022); Glucose Biosensor Systems (Greater China) Holdings, Inc. (until Sep 19, 2019)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $4.2M | $3.1M | $3.1M | $1.3M | $437,146 |
| Operating income | -$12.6M | -$10.7M | -$10.3M | -$12.6M | -$8.3M |
| Net income | -$12.4M | -$10.6M | -$10.2M | -$10.6M | -$8.3M |
| Diluted EPS | -$8.44 | -$20.04 | -$6.38 | -$127.00 | — |
| Operating cash flow | -$11.9M | -$9.7M | -$9.6M | -$7.4M | -$3.4M |
| Free cash flow | -$12.1M | -$9.9M | -$9.8M | — | — |
| Total assets | $11.9M | $8.2M | $13.8M | $10.4M | $12.4M |
| Total liabilities | $6.7M | $5.4M | $5.6M | $6.7M | $5.8M |
| Stockholders' equity | $5.5M | $3.0M | $8.3M | $3.8M | $6.6M |
| Cash and investments | $4.0M | $1.0M | $6.3M | $1.5M | $8.2M |
| Total debt | $1.8M | $84,659 | $356,158 | $579,612 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Nov 2, 2026 | Jun 30, 2026 |
| 10-K/A | Amended annual report | Oct 21, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Oct 13, 2026 | Oct 12, 2026 |
| 8-K |
Current report
Other events
|
Sep 11, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 2, 2026 | Aug 31, 2026 |
All 467 Intelligent Bio Solutions Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.